Skip to content

Tirzepatide

FDA-Approved• Prescribable
peptideInjection

Active ingredient in Mounjaro/Zepbound. Dual GLP-1/GIP agonist — more effective than semaglutide. SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks.

Key Facts

  • Classification
    Tirzepatide is a dual GIP/GLP-1 receptor agonist with C-20 fatty diacid for weekly dosing.
  • Primary Benefits
    Fat Loss (10/10) · Longevity (5/10) · Gut Health (3/10)
  • Administration
    Injection
  • Typical Dose
    Start at 2.5 mg per week and gradually increase to 5-15 mg per week. Meant for long-term use.
  • Evidence Strength
    Strong — 21 peer-reviewed studies referenced · Community sentiment 9/10
  • Stacks Well With
    5-Amino-1MQ, MOTS-c, BPC-157
  • Legal Status
    FDA-Approved · prescription required · WADA prohibited

Quick Facts

From price
$110
Type
peptide
Administration
Injection
Evidence
strong
Studies referenced
21
Community sentiment
9/10
Stacks with
3 peptides
Regulatory
FDA-Approved

Top benefits

🔥 Fat Loss
10/10
⏳ Longevity
5/10
🫃 Gut Health
3/10
View PricingCompare
1

Week 1–2

Appetite reduction more pronounced than GLP-1-only agonists. Nausea possible during titration. Early satiety. Start at 2.5mg and titrate slowly.

2

Week 3–6

Significant weight loss acceleration. Improved insulin sensitivity measurable on labs. Reduced cravings. GI side effects diminishing with dose adaptation.

3

Week 8+

Continued weight loss acceleration (5-10% at this stage, building to 15-22% over 72+ weeks in SURMOUNT trials). Improved lipid profiles, HbA1c, and liver enzymes. Potential reversal of hepatic steatosis. Sustained appetite control.

Common Side Effects

Nausea (common during titration)DiarrheaConstipationDecreased appetite (therapeutic effect)Injection site reactionsGallstones (rare)
Tolerance: GI side effects improve within 4-8 weeks at each dose level. Metabolic benefits sustained long-term
Cycling: Continuous use for weight/metabolic management. Gradual dose titration up over 16-20 weeks. Weight regain likely upon cessation.

Scientific Overview

Tirzepatide is a dual GIP/GLP-1 receptor agonist with C-20 fatty diacid for weekly dosing. SURMOUNT-1 showed up to 22.5% weight reduction at 72 weeks. Dual incretin mechanism produces greater insulin sensitization than GLP-1-only agonists, with additional effects on lipid metabolism and hepatic steatosis.

Dosing

Start at 2.5 mg per week and gradually increase to 5-15 mg per week. Meant for long-term use.

Reconstitution, storage, injection sites & timing

Benefit Profile

🔥 Fat Loss
10/10
⏳ Longevity
5/10
🫃 Gut Health
3/10
🧊 Inflammation
3/10
Medical oversight requiredNot safe during pregnancy· 5 contraindications